Valeant Pharmaceuticals Intl Inc. Cleans Shop. Is it a Buy Now?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is looking to turn around with operational changes. However, it’s not a buy until it has a plan for that debt.

| More on:
The Motley Fool

On Wednesday, outgoing CEO Michael Pearson and one of the largest investors, Bill Ackman, testified before the Senate in connection to Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) raising the prices of drugs, in some cases 500-1,000%.

During the testimony, Ackman revealed that new Valeant CEO, Joseph Papa, will begin working on Monday and receive the majority of his compensation based on stock-price recovery.

Papa is leaving Perrigo Company plc, a manufacturer of private label over-the-counter drugs. Along with Papa’s arrival, five directors will be stepping down by the end of the week with four new ones replacing them. According to the Wall Street Journal, these new board members will come from traditional pharmaceutical firms to help Valeant push forward.

But as investors, is this an opportunity to start buying shares in a company that were trading at over $300 a share less than a year ago?

At this point, I still don’t feel comfortable investing in Valeant for a few reasons. The first has to do with its debt. It is sitting on $30 billion in owed money because of its strategy of acquiring other pharmaceutical companies at a rapid pace. But debt alone is not a problem if the creditors are amenable to a rebuild. Pennies on the dollar never make lenders happy, so if there’s a path forward, I imagine they’ll take it.

But the real problem is that it has yet to release its annual report. Without that, it could default on its loans, and that would seriously hurt its ability to pay back its loans. Valeant has promised to have this documentation by April 29. For me, this is the real catalyst.

If Valeant can get its annual report out and begin operating like a legitimate business, it could have a future. While we look at how beaten down the company is, it’s important to remember that behind that $30 billion in debt, there really are a lot of great drugs. It owns Bausch & Lomb, which is a booming business. It owns Xifixan, a gastrointestinal drug with estimated future sales of $1 billion a year. Other products are Obagi and Solta, which are aesthetics products. And there’s CeraVe, a skincare product.

The reality is that Valeant owns a lot of really great assets, so if the company can deliver on its report and then start getting aggressive with paying down its debt, there could be a serious opportunity for investors. How much of that debt could be wiped off if Bausch & Lomb were sold? Some analysts have suggested upwards of 66% of the debt would be gone.

My recommendation for a company like Valeant is patience. While it is true that investors could see 200-400% increases, especially if it returns to its all-time highs, Valeant could also burn up. And when a company like Valeant goes away, common stock shareholders are considered last in the pecking order of asset distribution. Lenders come first.

Therefore, I would advise investors to keep this stock in their “research” column, keep track of it, but wait until the company starts to show some seriously good news. If it sells a product, gets its report out, or demonstrates a plan to get its debt under control, I’d suggest buying. Until then, I don’t view the risk/reward ratio being all that impressive yet.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

A worker uses a double monitor computer screen in an office.
Dividend Stocks

2 of the Best Canadian Stocks That Pay Out Monthly

These two Canadian dividend stocks are some of the best to buy, offering yields upwards of 5.4% and returning cash…

Read more »

Oil pumps against sunset
Energy Stocks

Suncor Stock: How Low Could it Go in 2023?

Suncor (TSX:SU) is up on the back of a bounce in oil prices but remains out of favour. Can new…

Read more »

clock time
Dividend Stocks

How Investors Can Build a $1 Million Portfolio in 12 Years

If you can handle it, you can certainly create a million-dollar portfolio in just 12 years, especially considering this dividend…

Read more »

Various Canadian dollars in gray pants pocket
Dividend Stocks

Passive-Income Seekers: 4 Safe Dividend Stocks to Own Beyond 2033

Dividend stocks are great, but only if they continue to perform after downturns as well. In the case of these…

Read more »

stock analysis
Tech Stocks

Investing in AI: 1 Cheap Tech Stock Poised for Growth

Docebo is a little-known Canadian tech firm that's unlocking the power of next-generation AI technologies.

Read more »

A close up image of Canadian $20 Dollar bills
Dividend Stocks

4 Big Dividend-Paying Stocks for 2023

These four stocks all earn strong cash flow and offer attractive dividend yields, making them some of the best to…

Read more »

A airplane sits on a runway.

1 Growth Stock Down 40% to Buy Right Now

This Canadian stock has years of growth potential, and considering the significant discount it trades at now, it's a top…

Read more »

grow dividends
Dividend Stocks

This 7.5 Percent Dividend Stock Pays Cash Every Month

If you need cash now, this dividend stock is certainly one I would consider that could double in share price…

Read more »